Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients

Efavirenz (EFV) is used in first-line antiretroviral (ARV) therapy of HIV-infected patients, and is principally metabolised by CYP1A2, CYP2A6, CYP2B6, CYP3A4/5 and the drug transporter ABCB1. Genetic variability in the above genes may contribute to differences in EFV plasma concentrations which affect the levels of viral suppression as well as development of side effects in patients. The aim of this project was to evaluate the effects of the different genetic polymorphisms on EFV plasma concentration levels in HIV/AIDS patients receiving first-line antiretroviral treatment (ART) containing EFV.

Grantor dc:publisher.institution

Department of Medicine

Year dc:date.issued

2011

Author dc:creator

• Swart, Marelize

Advisor dc:contributor.advisor

• Dandara, Collet

Language dc:language.iso

eng

Handle dc:identifier.uri

http://hdl.handle.net/11427/11835

OAI identifier oai:identifier

oai:open.uct.ac.za:11427/11835